Erythropoiesis-stimulating agents in sickle cell anaemia.
作者信息
Han Jin, Zhou Jifang, Kondragunta Vinod, Zhang Xu, Molokie Robert E, Gowhari Michel, Hassan Johara, Jain Shivi, Calip Gregory S, Gordeuk Victor R, Saraf Santosh L
机构信息
Division of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, IL, USA.
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA.
出版信息
Br J Haematol. 2018 Aug;182(4):602-605. doi: 10.1111/bjh.14846. Epub 2017 Jul 27.
Abstract
摘要
相似文献
1
Erythropoiesis-stimulating agents in sickle cell anaemia.
Br J Haematol. 2018 Aug;182(4):602-605. doi: 10.1111/bjh.14846. Epub 2017 Jul 27.
2
Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Clin Ther. 2014 Apr 1;36(4):594-610. doi: 10.1016/j.clinthera.2014.02.007. Epub 2014 Mar 18.
3
Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
J Nippon Med Sch. 2015;82(1):21-6. doi: 10.1272/jnms.82.21.
4
Evaluation of the effect of voxelotor and darbepoetin alfa on hemoglobin levels in patients with sickle cell disease.
Expert Rev Hematol. 2024 Jun;17(6):255-260. doi: 10.1080/17474086.2024.2352497. Epub 2024 May 16.
5
Darbepoetin Administration in Term and Preterm Neonates.
Clin Perinatol. 2015 Sep;42(3):557-66. doi: 10.1016/j.clp.2015.04.016. Epub 2015 May 23.
6
Darbepoetin alfa for anemia with myelodysplastic syndrome.
Expert Rev Hematol. 2015 Apr;8(2):139-46. doi: 10.1586/17474086.2015.1000854. Epub 2015 Jan 12.
7
Preschool Assessment of Preterm Infants Treated With Darbepoetin and Erythropoietin.
Pediatrics. 2016 Mar;137(3):e20153859. doi: 10.1542/peds.2015-3859. Epub 2016 Feb 15.
8
Guidelines for using darbepoetin alfa in patients with chemotherapy-induced anemia.
Pharmacotherapy. 2003 Dec;23(12 Pt 2):110S-118S. doi: 10.1592/phco.23.16.110s.31970.
9
Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
Ren Fail. 2008;30(8):778-83. doi: 10.1080/08860220802248977.
10
An overview of the pharmacokinetic disposition of darbepoetin alfa.
Pharmacotherapy. 2002 Sep;22(9 Pt 2):133S-140S. doi: 10.1592/phco.22.14.133s.33396.
引用本文的文献
1
Inhibition of sodium-glucose cotransporter-2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model.
J Cell Mol Med. 2024 Sep;28(17):e70091. doi: 10.1111/jcmm.70091.
2
Hemolysis-driven IFNα production impairs erythropoiesis by negatively regulating EPO signaling in sickle cell disease.
Blood. 2024 Mar 14;143(11):1018-1031. doi: 10.1182/blood.2023021658.
3
Sickle Cell Disease and CKD: An Update.
Am J Nephrol. 2024;55(1):56-71. doi: 10.1159/000534865. Epub 2023 Oct 27.
4
Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.
Blood. 2022 May 19;139(20):3030-3039. doi: 10.1182/blood.2021013873.
5
The nephropathy of sickle cell trait and sickle cell disease.
Nat Rev Nephrol. 2022 Jun;18(6):361-377. doi: 10.1038/s41581-022-00540-9. Epub 2022 Feb 21.
6
Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research.
Pediatr Blood Cancer. 2020 Dec;67(12):e28703. doi: 10.1002/pbc.28703. Epub 2020 Sep 17.
7
The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research.
Front Physiol. 2019 Mar 26;10:304. doi: 10.3389/fphys.2019.00304. eCollection 2019.
本文引用的文献
1
Identification and Validation of a Sickle Cell Disease Cohort Within Electronic Health Records.
Acad Pediatr. 2017 Apr;17(3):283-287. doi: 10.1016/j.acap.2016.12.005. Epub 2016 Dec 13.
2
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.
Haematologica. 2006 Aug;91(8):1076-83.
3
F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study.
Blood. 1993 Jan 1;81(1):9-14.
4
On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
Acta Haematol. 1995;94(3):128-34. doi: 10.1159/000203994.
5
Erythropoietin and renal function in sickle-cell disease.
Br Med J (Clin Res Ed). 1982 Dec 11;285(6356):1686-8. doi: 10.1136/bmj.285.6356.1686.
6
Sickle cell anemia patients have low erythropoietin levels for their degree of anemia.
Blood. 1986 Jan;67(1):46-9.
7
Erythropoietin in anemia of renal failure in sickle cell disease.
N Engl J Med. 1991 Oct 17;325(16):1175-6. doi: 10.1056/NEJM199110173251614.
8
Erythropoietin for anemia of renal failure in sickle cell disease.
N Engl J Med. 1991 May 9;324(19):1369-70. doi: 10.1056/NEJM199105093241916.
9
Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
N Engl J Med. 1990 Aug 9;323(6):366-72. doi: 10.1056/NEJM199008093230602.
10
Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure.
Nephrol Dial Transplant. 1992;7(8):817-21.
Zotero 插件